PATENT CLAIM ANALYSIS

Application Number: 15967442
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "001850"]

Abstract:
Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

Claim (Index 15):
The method of  claim 11 , wherein the anti-androgen compound is a gonadotropin-releasing hormone antagonist, a gonadotropin-releasing hormone agonist, a luteinizing hormone-releasing hormone agonist, or a luteinizing hormone-releasing hormone antagonist.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15508391', '15062740', '15346743', '15135151', '15222734']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7703919838316793
- 35 USC 102 Novelty (BERT): 0.5247184074592253
- Combined Prediction Score: 0.7458246261944339
- Mean Citation Score: 314.46507800000006
- Max Citation Score: 329.28775
- Similarity Product: 221.3571844242812

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test